Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM) held its first Capital Markets Briefing from 08:00 to 10:30 EST/14:00-16:30 CET on 21 June 2018 in New York, NY, and through a live webcast.

To re-watch the webinar please click here:

For a copy of the slide deck please click here:

During the Capital Markets Briefing, Pharming discussed its ongoing activities and the strategy for its growing research and development pipeline both for its recombinant human C1 esterase inhibitor (rhC1INH) and new protein replacement products.  The briefing was intended to inform shareholders, potential investors and other interested parties about Pharming’s current and planned activities in the areas of:

  • New development of its lead product RUCONEST® (rhc1inh) within the hereditary angioedema (HAE) space to meet patients’ needs;
  • New development of rhc1inh outside the HAE space to tackle other major unmet medical needs for which there are no current approved or effective therapies; and
  • Clinical development of new protein replacement products which address significant shortcomings of existing therapies.

The Briefing included presentations from top key opinion leaders in the main indications of interest.  Of note, Professor Marc Riedl, Professor of Medicine at the University of California, San Diego and Clinical Director of the US HAEA Angioedema Center and a world expert on the diagnosis, treatment and etiology of hereditary angioedema, and Professor Gustaaf Dekker, of the school of Obstetrics and Gynaecology at the University of Adelaide and a world expert on the etiology and treatment of pre-eclampsia, presented.

An outline of the agenda for the Capital Markets Briefing is detailed below:

  • Introduction – Dr Sijmen de Vries, Chief Executive Officer
  • HAE therapeutics overview (acute and prophylaxis indications) – Professor Marc Riedl, US HAEA Angioedema Center at UCSD
  • HAE US market overview – Stephen Toor, Pharming US General Manager
  • Building the RUCONEST® franchise– Professor Bruno Giannetti, Chief Operating Officer
  • rhC1INH development for the treatment/prevention of pre-eclampsia – Professor Gustaaf Dekker, University of Adelaide
  • Contrast-induced nephropathy and cardiac protection – Professor Bruno Giannetti
  • Protein replacement therapies in Pompe and Fabry diseases – Professor Bruno Giannetti
  • Pharming’s new commercial potential – Robin Wright, Chief Financial Officer
  • Summary – Dr Sijmen de Vries

Should you have any questions or comments regarding this webinar, please direct them to our email address.